Anticoagulants Market (By Indication of disease: Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others; By Administration Route: Oral, Injectable; By Drug Class: NOACs, Heparin & LMWH, Vitamin K Antagonist, Others; By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacy, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Anticoagulants Market 

5.1. COVID-19 Landscape: Anticoagulants Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Anticoagulants Market, By Indication of disease

8.1. Anticoagulants Market, by Indication of disease, 2024-2033

8.1.1. Pulmonary Embolism (PE)

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Deep Vein Thrombosis (DVT)

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Atrial Fibrillation

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Heart Attacks

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Anticoagulants Market, By Administration Route

9.1. Anticoagulants Market, by Administration Route e, 2024-2033

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Injectable

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Anticoagulants Market, By Drug Class 

10.1. Anticoagulants Market, by Drug Class, 2024-2033

10.1.1. NOACs

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Heparin & LMWH

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Vitamin K Antagonist

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Anticoagulants Market, By Distribution Channel 

11.1. Anticoagulants Market, by Distribution Channel, 2024-2033

11.1.1. Hospitals Pharmacies

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Online Pharmacy

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Anticoagulants Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.1.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.1.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.2.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.2.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.3.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.3.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.4.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.4.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.5.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.5.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Indication of disease (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Administration Route (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Drug Class (2021-2033)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 13. Company Profiles

13.1. Johnson & Johnson

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bristol-Myers Squibb Company

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Daiichi Sankyo Company

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Bayer AG

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. BoehringerIngelheim GmbH

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Aspen Holdings

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. GlaxoSmithKline Plc

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Pfizer Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sanofi S.A.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Portola Pharmaceuticals

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample